BCIQ Profiles

Company Profile Report
0319 ECP Blackfynn
BioCentury & Getty Images

Emerging Company Profile

Blackfynn: optimizing trial design for neurodegenerative therapies

Emerging Company Profile: Blackfynn aims to bring deprioritized late-stage neurodegenerative disease programs to market

Blackfynn is using its platform to redesign trials for neurodegenerative therapies, starting with an in-licensed Phase III-ready asset for Parkinson’s disease. 

Mar 20, 2021 | 1:38 AM GMT

Blackfynn has pivoted from a data service company to a drug developer that in-licenses clinical assets

Read the full 708 word article

How to gain access

Continue reading with a
two-week free trial.